Recent Finacing
Recent Raise
NodThera discovers and develops selective small‑molecule NLRP3 inflammasome inhibitors, advancing lead NT‑0167 in Phase 1 human safety, PK/PD studies and developing brain‑penetrant candidates for CNS and inflammatory indications.
